Navigation Links
Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Date:4/15/2009

Monday poster honored with special recognition awarded to top-rated abstracts

CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company's TransKingdom RNA interference (tkRNAi) technology will be the focus of three poster sessions featuring late-breaking research at the American Association for Cancer Research (AACR) meeting. The poster presentation scheduled for Monday afternoon, Safety and Efficacy of a tkRNAi Therapeutic Targeting Beta-Catenin (CTNNB1), received special recognition from the AACR Program Committee, which rated the abstract in the top three to four percent of those submitted. The AACR meeting will be held April 18 - 22, 2009, at the Colorado Convention Center in Denver, Colorado.

    Sunday, April 19  Characterization of a Multiple Hairpin Expression
                      Construct for TransKingdom RNA Interference (tkRNAi)
    8 am - noon
    Hall B-F          Cequent's Group Leader for Molecular Biology, Dr.
    Poster Section 27 AJ Wang will present data demonstrating that a single
    Poster board #10  tkRNAi construct can target multiple genes
    Abstract # LB-38  simultaneously and induce significant gene silencing.
                      Data presented here targets oncogenes relevant for
                      colon cancer, but this tkRNAi technology may also
                      prove useful in treatments for other cancers,
                      inflammatory diseases, and disorders

    Monday, April 20  Safety and Efficacy of a tkRNAi Therapeutic Targeting
                      Beta-Catenin (CTNNB1)
    1 - 5 pm
    Hall B-F          Cequent's Director of Development, Alison Silva, will
    Poster Section 15 present novel data showing the safety and efficacy of
    Poster board #26  orally applied tkRNAi in non-human primates against
    Abstract #LB-123  beta-catenin. These findings open the door to clinical
    Highly Rated      Phase I testing of Cequent's lead drug candidate
     Poster           CEQ508, an orally administered tkRNAi therapeutic
     Presentation     targeting the primary oncogene (beta-catenin, CTNNB1)
                      in FAP (familial adenomatous polyposis). FAP is an
                      inherited gastrointestinal disease that causes hundreds
                      of polyps to form in the colon. Today, without
                      prophylactic removal of the colon, people with FAP
                      almost inevitably develop colon cancer, and there is no
                      medical treatment available. Cequent's tkRNAi treatment
                      might provide a safe and effective tool to prevent the
                      formation of polyps and progression into cancer.

    Tuesday, April 21 Modulation of ABCB1-Mediated Multidrug Resistance (MDR)
                      by TransKingdom RNA Interference (tkRNAi)
    8 am - noon
    Hall B-F          Resistance against chemotherapy frequently complicates
    Poster Section 26 the clinical treatment of patients with cancer.
    Poster board #6   Professor Herman Lage of Charite University Hospital,
    Abstract #LB-199  Berlin, Germany, will present data describing the
                      targeting of chemotherapy resistance with tkRNAi. Here,
                      Professor Lage demonstrates the effectiveness of using
                      tkRNAi against an important multidrug resistance
                      mechanism seen in solid cancers such as gastric
                      carcinoma, ovarian cancer, and others.

About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
2. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
3. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
4. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
5. Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology
6. From eResearchTechnology to ERT
7. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
8. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
9. British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
10. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
11. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... ... Miracle Man: Against All Odds”: an inspiring affirmation of God’s work. “God's Miracle ... son of Minister Delores Pinnock and a Jamaican native who lives in Kingston and ... up in bed, I felt a pounding headache. It was like a drum beating ...
Breaking Medicine News(10 mins):